What is Oruka Therapeutics, Inc. (ORKA) stock price today?

Oruka Therapeutics, Inc. (ORKA) currently trades at $64.59 per share. The stock has a market capitalization of $4.18B and a P/E ratio of —x.

Is ORKA stock a buy, sell, or hold in 2026?

Based on WallStSmart's proprietary analysis, Oruka Therapeutics, Inc. has a Smart Value Score of 25/100 (Grade F), resulting in a "Strong Sell" investment rating. The Piotroski F-Score is 2/9 and Altman Z-Score is 16.41.

Is Oruka Therapeutics, Inc. financially healthy?

Oruka Therapeutics, Inc.'s Piotroski F-Score is 2/9 (weak financial health). The Altman Z-Score of 16.41 places it in the safe zone.

ORKA

Oruka Therapeutics, Inc.

NASDAQ: ORKA · HEALTHCARE · BIOTECHNOLOGY

$64.59

+0.81% today

Updated 2026-05-08

Market cap

$4.18B

P/E ratio

—

P/S ratio

—

EPS (TTM)

$-1.85

Dividend yield

—

52W range

$9 – $91

Volume

1.5M

Market cap

$4.18B

P/E ratio

—

P/S ratio

—

EPS (TTM)

$-1.85

Dividend yield

—

52W range

$9 – $91

Volume

1.5M

WallStSmart proprietary scores

out of 100

Grade: F

Strong Sell

Investment rating

4.3

Growth

7.3

Quality

B+

3.0

Profitability

5.0

Valuation

C+

2/9

Piotroski F-Score

Weak

16.4

Altman Z-Score

Safe zone

—

Industry rank

—

View all highly rated stocks (75+) →194 stocks currently score above 75

Price targets

Analyst target

$142.17

+120.11%

12-Month target

—

Intrinsic (DCF)

—

Margin of safety

—

2 Strong Buy11 Buy0 Hold0 Sell0 Strong Sell

Price chart

Stock snapshot

Strengths

+ Altman Z 16.41 — safe zone

Risks

- Piotroski 2/9 — weak financial health

- Thin margins at 0.00%

- Negative free cash flow $-22.66M

Key financials

Revenue Net Income Free Cash Flow

Metric	2022	2023	2024	2025	TTM
Revenue	—	—	—	$0.00	$0.00
Net income	$-9.93M	$-5.34M	$-83.72M	$-105.43M	$-29.58M
EPS	—	—	—	—	$-1.85
Free cash flow	$-18.80M	$-10.91M	$-58.03M	$-88.42M	$-22.66M
Profit margin	—	—	—	—	—

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
ORKA	$4.18B	25	4.3	3.0	5.0	7.3	—	Avoid
LLY	$869.41B	78	10.0	10.0	5.0	6.5	—	Strong Buy
JNJ	$535.63B	59	4.7	9.0	3.3	6.0	-37.47%	Buy
ABBV	$358.55B	63	4.0	8.0	4.0	5.0	-19.74%	Buy
UNH	$335.78B	54	5.3	5.5	7.3	4.8	+40.60%	Buy
AZN	$286.68B	62	6.0	8.5	5.3	5.0	+6.60%	Buy

Smart narrative

Oruka Therapeutics, Inc. trades at $64.59. Our Smart Value Score of 25/100 indicates the stock is weak. The company scores 2/9 on the Piotroski F-Score. With an Altman Z-Score of 16.41, it sits in the safe zone.

Frequently asked questions

What is Oruka Therapeutics, Inc.'s stock price?

Oruka Therapeutics, Inc. (ORKA) trades at $64.59.

Is Oruka Therapeutics, Inc. overvalued?

Smart Value Score 25/100 (Grade F, Strong Sell).

What is the price target of Oruka Therapeutics, Inc. (ORKA)?

The analyst target price is $142.17, representing +120.1% upside from the current price of $64.59.

Piotroski F-Score?

2/9 — weak financial health.

Altman Z-Score?

16.41 — safe zone.

Company info

SectorHEALTHCARE

IndustryBIOTECHNOLOGY

CountryUSA

ExchangeNASDAQ

CurrencyUSD

Quick metrics

P/S ratio—

ROE-24.70%

Beta—

50D MA$51.83

200D MA$31.46

Shares out0.06B

Float0.04B

Short ratio—

Avg volume1.5M

Performance

1 week—

1 month—

3 months—

YTD—

1 year—

3 years—

5 years—

Compare

ORKA vs LLY →ORKA vs JNJ →ORKA vs ABBV →Stock screener →